ArticleActa oncologica (Stockholm, Sweden)2025
Pembrolizumab as first-line treatment for recurrent and metastatic head and neck cancer - real-world single-centre data.
Bogdana Patachi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.